By I. Ugo. University of Rio Grande. 2019.
Hagar RW proven caverta 50mg, Michlitsch JG discount caverta 100mg on line, Gardner J generic caverta 100mg without a prescription, Vichinsky EP, Morris CR. Prospective echocardiography with sickle cell disease. Pulmonary hypertension children with sickle cell disease. Pulmonary hypertension in sickle children with sickle cell disease. Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Lee MT, Small T, Khan MA, Rosenzweig EB, Barst RJ, Brittenham follow up of elevated pulmonary artery pressures in children with sickle GM. Doppler-deﬁned pulmonary hypertension and the risk of death in cell disease. Elevated tricuspid disease during treatment with hydroxyurea. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Longitudinal study of echocardiog- to 9 years of treatment. Fitzgerald M, Fagan K, Herbert DE, Al-Ali M, Mugal M, Haynes J Jr. Misclassiﬁcation of pulmonary hypertension in adults with sickle 44. The effect of prolonged hemoglobinopathies using Doppler echocardiography. Ataga1,2 1Division of Hematology/Oncology and 2Comprehensive Sickle Cell Program, Department of Medicine, University of North Carolina, Chapel Hill, NC A 27-year-old man with sickle cell disease (HbSS) presents to the sickle cell clinic for follow-up after a screening echocardiogram revealed an increased tricuspid regurgitant velocity of 2. He has a history of 2 painful crises per year and has been hospitalized 3 times over the past 10 years for management of painful crises. He had one episode of acute chest syndrome at age 15 that was treated with an RBC exchange transfusion, supplemental oxygen, and intravenous antibiotics; he did not require mechanical ventilation. He has not had additional episodes of acute chest syndrome and does not have a history of stroke, retinopathy, or leg ulcers. The patient has never been treated with hydroxyurea. He wants to know whether hydroxyurea will prevent future pulmonary complications related to sickle cell disease. We Introduction then restricted the search to include only articles with “acute chest Hydroxyurea (HU) gained approval for the treatment of adults with syndrome” OR “pulmonary” as text words (Figure 1). We reviewed sickle cell anemia from the US Food and Drug Administration in the abstracts of each of these studies and excluded publications that 1998. The positive clinical effects of HU are thought to be largely did not evaluate and report the relationship between HU and acute mediated by the medication’s ability to induce the expression of chest syndrome or PH/increased TRV in at least 2 patients with fetal hemoglobin (HbF) in RBCs; low levels of HbF are one of the HbSS disease or HbS 0-thalassemia. We then reviewed the full strongest predictors of morbidity and mortality in sickle cell disease texts of the remaining articles and excluded additional studies based (SCD). Finally, we added articles identiﬁed as relevant deformability that lessen the rate of hemolysis, and its ability to from the reference lists of the included studies, bringing the total lower the number of circulating WBCs likely leads to decreased number of publications included in this review to 27. The study endothelial inﬂammation and vasoocclusion. In addition, it releases a nitric oxide moiety that not only decreases platelet and coagulation activation, but may also lessen endothelial For ACS, there were 5 publications reporting the results of 3 injury through its vasodilatory effects. Long-term use Two of these RCTs (one in adults, one in children) compared HU of HU has been reported to reduce mortality and improve health- with placebo; the other compared HU and phlebotomy with chronic related quality of life in individuals with SCD. The remaining publications on ACS described uncontrolled Pulmonary complications of SCD include acute chest syndrome longitudinal studies, retrospective case series, or prospective cohort (ACS), pulmonary hypertension (PH), pulmonary artery thrombo- studies using historical controls. Steinberg et al15 reported on long-term follow-up of (RHC). Bcause reported all pulmonary complications as a single exposure variable the majority of studies of pulmonary complications in SCD have when examining patients’ causes of death. Voskaridou et al16 432 American Society of Hematology In addition to the aforementioned RCTs, we found 9 studies of various designs that also showed that HU decreased the occurrence of ACS. Overall, there is moder- ately strong evidence that HU signiﬁcantly reduces the risk of ACS in patients with SCD. Pulmonary hypertension Ten of 12 studies of PH in SCD were limited by their use of echocardiograms, which have a positive predictive value for PH in SCD of only 25%–31%. Studies examining HU’s impact on increased TRV are presented in Table 2. As a whole, the studies we identiﬁed that examined the relationship of HU use to increased TRV provided inconsistent evidence of HU’s effect. Articles were excluded if they did not report the relationship between hydroxyurea and There were 2 studies that initially evaluated all patients with an acute chest syndrome or pulmonary hypertension. MeSH medical echocardiogram and later performed RHC in patients with TRV 2. Fonseca et al42 performed 2 separate comparisons: 1 for patients with TRV 2. Parent et al made 1 comparison of 3 groups: those did not specify how PH was diagnosed. Neither study showed a ACS difference between or among any of the groups in terms of We found moderate-quality evidence showing that HU reduces the proportions of patients taking HU at the time of evaluation. The 2 randomized, studies of increased TRV, these studies of PH as diagnosed by RHC placebo-controlled trials that evaluated the effects of HU compared do not provide evidence that HU prevents PH. However, the lack of with placebo were well performed and suffer from no major 10,14 randomization and prospective follow-up makes further interpreta- weaknesses. However, ACS was not the primary study outcome tion of these results difﬁcult. It is possible that a large treatment in either trial. The Multicenter Study of Hydroxyurea (MSH) trial, effect could have been masked by selection bias in these studies. The Pediatric Pulmonary complications Hydroxyurea in Sickle Cell Anemia (BABY HUG) study enrolled Two studies reported results from long-term follow-up of patients 299 children aged 9-18 months between 2003 and 2007. Steinberg et al15 of ACS was signiﬁcantly reduced in patients receiving HU (hazard described the most frequent causes of death for 299 patients 17. A subset analysis years after they had been enrolled in the MSH trial. At the time of the on ACS incidence in young children was most pronounced in follow-up publication, 24% of all deaths were due to pulmonary patients with baseline hemoglobin values in the lowest quartile. The Laikon Study of Hydroxyurea in Sickle Cell Syndromes (LaSHS) was a nonrandomized trial of HU in patients with SCD The Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) (HbSS, HbS 0-thalassemia, and HbS -thalassemia) that assigned trial was an RCT that compared the use of HU and phlebotomy with patients to receive HU based on disease severity criteria.
Patients who failed to respond the therapy were eligible for escape at week 16 so we considered the results in the placebo-controlled phase up until week 14 buy 50 mg caverta with amex. Significantly more patients in the golimumab groups achieved the primary outcome of an American College of Rheumatology 20 response at week 14 (golimumab 50 mg 51% buy caverta 50mg mastercard, golimumab 100 mg 45% purchase 100mg caverta with mastercard, placebo 9%, P<0. Likewise, the improvement in the physical component summary score for the SF-36 instrument (which measures quality of life) were significantly better in both golimumab groups compared with Targeted immune modulators 62 of 195 Final Update 3 Report Drug Effectiveness Review Project placebo (mean ± SD: golimumab 50 mg 6. Infliximab 176,177 We identified two high-quality meta-analyses on the general efficacy of infliximab. Both reviews pooled the results for two trials of infliximab compared with placebo, with 304 patients. Pooled results presented statistically significantly greater improvements of infliximab- than placebo-treated patients on all included outcome measures. The relative risk for achieving the Psoriatic Arthritis Response Criteria was 3. In like fashion the infliximab treated patients were more likely to achieve an American College of Rheumatology 20 (relative risk, 5. In both studies patients were randomized to 5 mg/kg of infliximab or placebo at weeks 0, 2, 6, 186 187 14, and 16 (total of 16 weeks), or weeks 0, 2, 6, 14, and 22 (total of 22 weeks). Improvement in quality of life (measured by the Health Assessment Questionnaire) was 186,187 statistically significantly greater for infliximab patients compared with placebo patients. In the larger study, at 14 weeks the mean improvement was 48. Ustekinumab We identified one multi-center trial of 146 patients with active psoriatic arthritis randomized to 181,182 ustekinumab 63-90 mg per dose or placebo for 12 weeks. Significantly more patients who received 12 weeks of ustekinumab achieved the primary outcome of an American College of Rheumatology 20 response than those who received placebo for the first 12 weeks of the trial 181 (42% vs. Likewise, 60% of patients in the ustekinumab group achieved a response on the Dermatology Life Quality Index compared with 25% of the placebo 182 patients (P<0. Psoriatic Arthritis in Children No evidence on the comparative effectiveness of targeted immune modulators for the treatment of psoriatic arthritis in children exists. In addition, no placebo-controlled trials on children with psoriatic arthritis are evident in the literature. Crohn’s Disease The following drugs are currently approved by the US Food and Drug Administration for the treatment of Crohn’s disease: adalimumab, certolizumab pegol, infliximab, and natalizumab. Summary of findings Overall, the strength of evidence on the comparative effectiveness of targeted immune modulators for the treatment of Crohn’s disease was insufficient (Table 13). We did not find any Targeted immune modulators 63 of 195 Final Update 3 Report Drug Effectiveness Review Project head-to-head randomized controlled trials or observational studies comparing one targeted immune modulator to another and evidence was insufficient to make indirect comparisons. We included one recent, good-quality systematic review and meta-analysis of all four targeted immune modulators approved by the US Food and Drug Administration for Crohn’s 190 disease. The review assessed two outcomes, failure of remission and relapse of disease activity, and analyzed the subgroup of patients with fistulizing disease separately. Overall, the 191-196 review included 27 randomized controlled trials: eight on adalimumab, seven on 197-201 202-208 209-213 certolizumab pegol, seven on infliximab, and six on natalizumab. Pooled results regarding the general efficacy of targeted immune modulators for Crohn’s disease showed consistent results. Infliximab demonstrated statistically significant greater efficacy than placebo for inducing remission and preventing relapse in all patients and in healing 190 and maintaining remission in fistulizing Crohn’s disease. Natalizumab was superior to placebo 190 in inducing remission and preventing relapse in patients with Crohn’s disease. Adalimumab demonstrated statistically significant greater efficacy than placebo for inducing remission. Both single trials on evaluating the efficacy of adalimumab for maintaining response demonstrated statistically significant greater efficacy than placebo. Certolizumab pegol was superior to placebo only in preventing relapse but there was a trend showing a greater efficacy than placebo in 190 inducing remission. Overall, Adalimumab and certolizumab pegol were not shown to be more efficacious compared with placebo for inducing remission and healing in fistulizing Crohn’s 190 disease. In particular, the evidence from currently available trials on investigating the efficacy of targeted immune modulators in patients with fistulizing Crohn’s disease was insufficient. We did not find any evidence that met our eligibility criteria on the general efficacy of abatacept, alefacept, anakinra, etanercept, golimumab, rituximab, tocilizumab, or ustekinumab for the treatment of Crohn’s disease. Although some studies allowed stable doses of other immunomodulatory agents, no conclusive evidence exists to determine whether combination treatment of targeted immune modulators with other agents (azathioprine, 6-mercaptopurine or methotrexate) leads to clinically and statistically greater improvements than monotherapy. We did not include studies of targeted immune modulators compared with active therapies for Crohn’s disease. We found no studies that met our eligibility criteria assessing the comparative or general efficacy of any targeted immune modulator in pediatric populations. Study populations and outcome measures Most of the included efficacy studies were conducted in narrowly defined populations and/or were limited to less than 1 year of follow-up. Generally, patients were allowed to remain on stable doses of corticosteroids in all trials. Some trials involved tapering of corticosteroids in the evaluation of maintenance. All patients suffered from active Crohn’s disease for at least 3 months. Some patients also had abdominal or perianal fistulas, a serious complication of Crohn’s disease characterized by abnormal connection between the gut and the skin with small bowel or colonic contents draining to the skin surface for at least 3 months. Most studies included patients with a Crohn’s Disease Activity Index score between 220 and 400. However, some trials included patients with Crohn’s Disease Activity Index scores as high as 450 (i. Disease duration and concomitant treatments varied across studies. On average, disease duration ranged from 8 to 12 years. Many studies allowed concomitant treatment with 5- aminosalicylate, antibiotics, corticosteroids, azathioprine, 6-mercaptopurine, or methotrexate. Targeted immune modulators 64 of 195 Final Update 3 Report Drug Effectiveness Review Project Most studies utilized the Crohn’s Disease Activity Index to characterize disease severity. The Crohn’s Disease Activity Index assesses eight related variables (e. Response commonly was characterized by a Crohn’s Disease Activity Index reduction greater than or equal to 70 points. Several studies utilized the Inflammatory Bowel Disease Questionnaire. This questionnaire identifies 32 individual items categorized within four major quality of life domains (primary bowel symptoms, systemic symptoms, social impairment, and altered emotional function). Some studies assessed surrogate parameters such as C-reactive protein concentrations as an objective marker for inflammation.
Impact of azacitidine before lenalidomide and azacitidine combination in patients with higher-risk allogeneic stem-cell transplantation for myelodysplastic syndromes: a myelodysplastic syndromes purchase caverta on line amex. Outcome of high-risk myelodysplas- in patients with the myelodysplastic syndrome (MDS): initial results of tic syndrome after azacitidine treatment failure buy genuine caverta. Very high rates of PD-L2 discount 50 mg caverta visa, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by clinical and cytogenetic response with the combination of the histone treatment with hypomethylating agents. Last marrow standing: bone marrow transplanta- azacitidine with or without entinostat for myelodysplastic syndrome and tion for acquired bone marrow failure conditions. Curr Hematol Malig acute myeloid leukemia with myelodysplasia-related changes: results of Rep. Swerdlow1 1University of Pittsburgh School of Medicine, Pittsburgh, PA Identiﬁcation of large B-cell lymphomas that are “extra-aggressive” and may require therapy other than that used for diffuse large B-cell lymphoma, not otherwise speciﬁed (DLBCL, NOS), is of great interest. Large B-cell lymphomas with MYC plus BCL2 and/or BCL6 rearrangements, so-called ‘double hit’ (DHL) or ‘triple hit’ (THL) lymphomas, are one such group of cases often recognized using cytogenetic FISH studies. Whether features such as morphologic classiﬁcation, BCL2 expression, or type of MYC translocation partner may mitigate the very adverse prognosis of DHL/THL is controversial. Classiﬁcation of the DHL/THL is also controversial, with most either dividing them up between the DLBCL, NOS and B-cell lymphoma, unclassiﬁable, with features intermediate between DLBCL and Burkitt lymphoma (BCLU) categories or classifying at least the majority as BCLU. The BCLU category itself has many features that overlap those of DHL/THL. Currently, there is growing interest in the use of MYC and other immunohistochemistry either to help screen for DHL/THL or to identify “double-expressor” (DE) large B-cell lymphomas, deﬁned in most studies as having 40% MYC and 50%-70% BCL2 cells. DE large B-cell lymphomas are generally aggressive, although not as aggressive as DHL/THL, are more common than DHL/THL, and are more likely to have a nongerminal center phenotype. Whether single MYC rearrangements or MYC expression alone is of clinical importance is controversial. The ﬁeld of the DHL/THL and DE large B-cell lymphomas is becoming more complex, with many issues left to resolve; however, great interest remains in identifying these cases while more is learned about them. Many of these frequently controversial questions are 2 groups of lymphomas difﬁcult to resolve because, in addition to the obvious issues of subjectivity (eg, with histopathologic classiﬁcation), the literature is very inconsistent in terms of entry criteria for clinical studies, Introduction diagnostic criteria, phenotypic and cytogenetic criteria, and therapeu- The inspiration for this session comes from a great desire on the part tic strategies—an important issue that I will not keep reminding the of pathologists and clinicians to identify large B-cell lymphomas reader about, but which may affect many of the reported discrepan- that cannot be categorized as one of the speciﬁc subtypes recognized cies that I highlight. Many of these cases end up together with speciﬁed other chromosomal rearrangements. There is growing interest now in the more chromosomal translocations, such as BCL3 at 9p13, or even common “double-expressor” (DE) lymphomas deﬁned based on CCND1. Major issues that remain a hot topic of discussion are the precise deﬁnition for the DH Leaving the more controversial issues to the discussion in the and DE large B-cell lymphomas, whether there are important following sections, DHLs are currently probably best restricted to subsets of these cases that need to distinguished for clinical or either DLBCL, NOS or BCLU that cannot be better classiﬁed as a biological purposes, whether MYC abnormalities in the absence of more speciﬁc type of lymphoma. For example, a mantle cell 90 American Society of Hematology lymphoma with a MYC and CCND1 translocation should still be diagnosed as a mantle cell lymphoma even if the MYC-R has additional clinicopathologic implications. Whereas one series showed a trend for a worse prognosis for the cases representing transformation, another found the presence of a preceding MYC-negative lymphoma not to make a difference (although, in that series, the overall survival was 6 months and most patients did not get Rituxan) and another showed no prognostic differences between patients with or without a prior history of lymphoma. As deﬁned in this way, 2%–12% of DLBCL (most studies 6%) and 32%–78% of BCLU are DHL, with the latter proportion being biased in some studies either because testing was performed on selected cases or because DH was used as a criterion for BCLU. Many have been identiﬁed in the past using classical cytogenetic techniques (Figure 1A); however, these require fresh tissue, are labor intensive, and the reality is that, in many lymphomas, they will not have been performed. Although of great utility for varied reasons, speciﬁc genes involved in translocations are inferred but not proven [eg, t(14;18)(q32;q21) can represent either a BCL2 or MALT1 transloca- tion] and cryptic translocations can also be missed. In one report, classical CG studies missed MYC-R in about half of the cases. FISH studies can be successfully per- formed in almost all cases using formalin-ﬁxed parafﬁn-embedded tissue sections, although smears, touch imprints, and fresh inter- phase or metaphase cells can also be used. A minimal workup to ﬁnd DHL includes normal fused signal and one set of separated red and green signals. There is one normal cell on the right with 2 fused probe is useful in picking up occasional cases missed by the MYC signals and an abnormal cell with 1 fused and 1 set of separated red and break-apart probe and also in identifying the MYC partner in a green signals. In one study, MYC What are the implications, associated controversies, rearrangements were detected only with the dual fusion probe in and ongoing questions related to the DHLs? Half of the MYC rearranged cases had an IG express B-cell antigens, with 64%–100% (most studies 80%) partner that was IGH in 58% of the translocated cases or either or having a germinal center (GC) rather than a non-GC/activated. A study of de novo DLBCL treated with immunochemotherapy B-cell (ABC) type phenotype/genotype as assessed mostly by published in abstract form also reported that only DHL with an IHC. Of greater concern, one study of a mixed group of cases associated with a FL. These investigators concluded that the DHL/ but not those with MYC gains (3-4 copies of MYC), which are much THL previously diagnosed as BL are a “very aggressive disease that more common. Overall survival reported no impact of “high-level” MYC ampliﬁcations ( 6 gene is very short…. Some report that cases that morphologically resemble hit” lymphomas (SHLs). Many of the earlier studies reporting the DLBCL rather than BCLU do better,14 although others ﬁnd that the adverse impact of MYC-R included both SHL and DHL without speciﬁc morphologic ﬁndings do not have prognostic implica- necessarily distinguishing them. Two of 3 long-term DHL In fact, some report that isolated MYC-Rs are not associated with an survivors in one study had 40% MYC cells and another reported adverse prognosis at all6,18,19 or are so only in cases of GC type that 5 of 8 patients with MYC-R but little MYC staining did not have (impact of any MYC-R lost in multivariate analysis once DHL are “events. Another study found a additional potential complexities to these analyses, it has also been signiﬁcant impact only among those with a GC phenotype. In a study of patients with DLBCL or BCLU, most but only 10 months versus 77 months for those with low MYC not all of whom received intensive therapy and Rituxan, only when expression. Although resembling a BL, there are more cells with single central nucleoli than would be typical and some irregular nuclear contours. The Ki-67 stain was extremely high but, unlike BL, the cells were CD10 negative and BCL2 positive (not illustrated). Nevertheless, these investigators stated that “… so-called genetic double-hit lymphomas … represent a true oncological challenge and are clearly under-treated by R-CHOP. BCLU with MYC and BCL2 double-hit and MYC and BCL2 Categorization of DHL is controversial. Note the extensive nuclear MYC (B) and cytoplasmic DH, putting all the cases in the BCLU category even if they BCL2 (C) expression fulﬁlling the criteria for a DE B-cell lymphoma. The morphologically resemble a DLBCL, dividing up the DHL cases lymphoma had a GC-type phenotype (CD10 , BCL6 , IRF4/MUM1 ) with some in each of these 2 categories based on their morphologic and 95% Ki-67-positive cells (not illustrated). Suggested evaluation of large B-cell lymphomas of DLBCL, NOS, and BCLU type Obtain clinical history* Routine histopathology Immunophenotypic studies to assess CD20 expression, cell of origin (CD10, BCL6 and IRF4/MUM1 if using Hans’ algorithm), Ki-67, MYC, BCL2, CD5 and cyclin D1 to accomplish the following: Identify B-cell lineage in absence of T-cell phenotype and required for use of anti-CD20 therapeutic antibodies Cell of origin has prognostic implications in many studies and may impact therapeutic decisions Identify MYC and BCL2 DE cases Identify cases more likely to be DHL/THL (see text and table 4) Identify blastoid and pleomorphic mantle cell lymphomas Identify CD5 DLBCL, a recognized immunophenotypic variant Aid in distinction from Burkitt lymphoma, exclude plasmablastic lymphoma, assist in distinction of other types of large B-cell lymphomas In situ hybridization for Epstein-Barr virus at least in cases that have some polymorphism and patient is 50 years old (rule out EBV DLBCL of the elderly) In the absence of classical cytogenetic studies, cytogenetic FISH studies to identify MYC, BCL2 and BCL6 rearrangements at least in a subset of cases more likely to have a positive yield† such as: All DLBCL with a GC phenotype plus cases of BCLU and/or a combination of the following with any positive ﬁnding being followed up with FISH studies (the more parameters selected the more cases tested and the fewer cases missed, none are 100% sensitive) MYC 40% (some recommend 20%) Ki-67 80% (a poor criterion used in isolation) BCL2 strongly positive (will miss most BCL6 DHL, may require use of 1 BCL2 antibody) MYC 40% and BCL2 50% (“DE” cases, see comments re MYC and BCL2 above) Histopathology suggests BCLU If MYC rearrangement is identiﬁed, demonstration of translocation partner has been shown to be of importance in limited studies (IGH/ / versus non-immunoglobulin partner) but would be considered more optional at the current time. Speciﬁcally, a workup to determine if very aggressive therapies are appropriate is not required if a patient’s performancestatusorothercircumstanceswouldprecludesuchatherapeuticapproach. The criteria, which at least in some studies would be the least predictive, are morphologic features and Ki-67 proportions and for thelesscommonBCL6DHL,BCL2expression. Practice patterns vary widely, even at academic institutions, with “dramatically different and usually rapidly fatal” clinical course many choosing either the second or third options, but with some unlike BL, with a median survival of only 0.
So far purchase caverta 100 mg free shipping, it is unknown whether this non-canonical HLA-II – restricted CD8 T cells exist also in humans and whether they can be induced by vaccination purchase 50mg caverta with mastercard. A promising approach for the development of more effective HIV-1 vaccines is the therapeutic immunization of HIV-1-infected patients on ART who then undergo a treatment interruption (Harrer 2005) generic caverta 100mg on line. The analysis of a vaccine’s ability to control HIV-1 replication during treatment interruption may be a good instrument in iden- tifying vaccines that are also effective in prevention. References Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombi- nant glycoprotein 120 vaccine to prevent HIV-1 infection. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV- 1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV- 1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV- 1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. Preventive HIV-1 Vaccine 51 Hansen SG, Platak M Jr, Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Cytomegalovirus vectors violate CD8+ T cell epitope recognition para- digms. Therapeutic vaccination of HIV-1-infected patients on HAART with a recom- binant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment inter- ruption. Antivir Ther 2005; 10:285-300 Harrer T, Harrer E, Kalams SA, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with pro- longed infection and low viral load. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. Quantification of CD8+ T lymphocytes responsive to human immunodefi- ciency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure. Human T cells expressing two additional receptors (TETAR) specific for HIV-1 provide new insights in antigen-induced TCR down-modulation. Preliminary results of safety and immunogenicity of Ad35-GRIN/ENV HIV Vaccine in HIV-uninfected subjects (IAVI B001). Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope gly- coprotein in complex with the CD4 receptor and a neutralizing human antibody. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. Preserved CD4+ central memory T cells and survival in vaccinated SIV-chal- lenged monkeys. Immunization with envelope subunit vaccine products elicits neu- tralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. Role of CTL-mediated immune selection in a dominant HLA-B8-restricted CTL epitope in Nef. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case—cohort analysis. Lessons learned from HIV-1 vaccine trials:new priorities and directions. Dual selection pressure by drugs and HLA class I-restricted immune responses on HIV-1 protease. The qualitative nature of the primary immune response to HIV infec- tion is a prognosticator of disease progression independent of the initial level of plasma viremia. Randomized, double-blind, placebo-controlled efficacy trial of a biva- lent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. Extended evaluation of the virologic, immunologic, and clini- cal course of volunteers who acquiredHIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX(R) B/E. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503:277-280 Wagner R, Leschonsky B, Harrer E, et al. Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: constraints on immune escape associated with targeting a sequence essential for viral replication.